Clinical Trials

Clinical trials in nuclear medicine. Sorted by date of last update.

Title	Phase	Last Update
Comparing Retreatment of Lu-177-DOTATATE PRRT versus the Usual Treatment in Patients with Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial Phase 2 Last update: January 2	Phase 2	January 2
Radiation Medication (Radium-223 Dichloride) versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy Phase 1 Last update: January 2	Phase 1	January 2
A Study to Test Radium-223 with Docetaxel in Patients with Prostate Cancer Phase 3 Last update: January 2	Phase 3	January 2
Lu-177-DOTA-EB-TATE in Adult Patients with Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer Phase 1 Last update: January 2	Phase 1	January 2
Dynamic Ga-68-PSMA and F-18-FDG PET/CT Analysis Prior to Lu-177-PSMA (PYPET) N/A Last update: January 2	N/A	January 2
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study Phase 2 Last update: January 2	Phase 2	January 2
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones Phase 2 Last update: January 2	Phase 2	January 2
Testing Lutetium Lu-177 Dotatate in Patients with Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors Phase 2 Last update: January 2	Phase 2	January 2
Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu-177 Dotatate) for Pancreatic Neuroendocrine Tumors Phase 1 Last update: January 2	Phase 1	January 2
Ga-68-NYM096/Lu-177-NYM096 in Metastatic ccRCC (NYCRRLT) Phase 1 Last update: December 31	Phase 1	December 31